Cellectar Biosciences Net Income
| CLRB Stock | USD 3.22 0.02 0.62% |
As of the 30th of January, Cellectar Biosciences shows the Standard Deviation of 6.47, insignificant risk adjusted performance, and Mean Deviation of 4.55. Cellectar Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cellectar Biosciences Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -40.1 M | -38.1 M | |
| Net Loss | -40.1 M | -38.1 M | |
| Net Loss | -25.7 M | -24.5 M | |
| Net Loss | (32.87) | (34.51) | |
| Net Income Per E B T | 0.90 | 0.74 |
Cellectar | Net Income | Build AI portfolio with Cellectar Stock |
Analyzing Cellectar Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Cellectar Biosciences's current valuation and future prospects.
Latest Cellectar Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Cellectar Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cellectar Biosciences financial statement analysis. It represents the amount of money remaining after all of Cellectar Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cellectar Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cellectar Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (44.58 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cellectar Net Income Regression Statistics
| Arithmetic Mean | (18,927,289) | |
| Coefficient Of Variation | (76.47) | |
| Mean Deviation | 12,305,903 | |
| Median | (13,562,290) | |
| Standard Deviation | 14,472,942 | |
| Sample Variance | 209.5T | |
| Range | 43.8M | |
| R-Value | (0.90) | |
| Mean Square Error | 40.7T | |
| R-Squared | 0.82 | |
| Slope | (2,592,260) | |
| Total Sum of Squares | 3351.5T |
Cellectar Net Income History
Other Fundumenentals of Cellectar Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cellectar Biosciences Net Income component correlations
Cellectar Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cellectar Biosciences is extremely important. It helps to project a fair market value of Cellectar Stock properly, considering its historical fundamentals such as Net Income. Since Cellectar Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cellectar Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cellectar Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. Projected growth potential of Cellectar fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cellectar Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Cellectar Biosciences requires distinguishing between market price and book value, where the latter reflects Cellectar's accounting equity. The concept of intrinsic value—what Cellectar Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cellectar Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Cellectar Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cellectar Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cellectar Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cellectar Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cellectar Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cellectar Biosciences.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Cellectar Biosciences on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Cellectar Biosciences or generate 0.0% return on investment in Cellectar Biosciences over 90 days. Cellectar Biosciences is related to or competes with AEON Biopharma, Bolt Biotherapeutics, Cingulate, Sensei Biotherapeutics, Lyra Therapeutics, Imunon, and Marker Therapeutics. Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercial... More
Cellectar Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cellectar Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cellectar Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 30.55 | |||
| Value At Risk | (10.25) | |||
| Potential Upside | 7.66 |
Cellectar Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectar Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cellectar Biosciences' standard deviation. In reality, there are many statistical measures that can use Cellectar Biosciences historical prices to predict the future Cellectar Biosciences' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | (0.12) |
Cellectar Biosciences January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 4.55 | |||
| Coefficient Of Variation | (5,640) | |||
| Standard Deviation | 6.47 | |||
| Variance | 41.91 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 30.55 | |||
| Value At Risk | (10.25) | |||
| Potential Upside | 7.66 | |||
| Skewness | 0.5397 | |||
| Kurtosis | 2.9 |
Cellectar Biosciences Backtested Returns
At this point, Cellectar Biosciences is slightly risky. Cellectar Biosciences secures Sharpe Ratio (or Efficiency) of 0.0268, which signifies that the company had a 0.0268 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Cellectar Biosciences, which you can use to evaluate the volatility of the firm. Please confirm Cellectar Biosciences' insignificant Risk Adjusted Performance, mean deviation of 4.55, and Standard Deviation of 6.47 to double-check if the risk estimate we provide is consistent with the expected return of 0.17%. Cellectar Biosciences has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.08, which signifies a somewhat significant risk relative to the market. Cellectar Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Cellectar Biosciences is expected to follow. Cellectar Biosciences right now shows a risk of 6.49%. Please confirm Cellectar Biosciences total risk alpha, accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and day median price , to decide if Cellectar Biosciences will be following its price patterns.
Auto-correlation | 0.46 |
Average predictability
Cellectar Biosciences has average predictability. Overlapping area represents the amount of predictability between Cellectar Biosciences time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cellectar Biosciences price movement. The serial correlation of 0.46 indicates that about 46.0% of current Cellectar Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.46 | |
| Spearman Rank Test | 0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.18 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cellectar Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cellectar Biosciences reported net income of (44.58 Million). This is 113.06% lower than that of the Biotechnology sector and 163.65% lower than that of the Health Care industry. The net income for all United States stocks is 107.81% higher than that of the company.
Cellectar Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectar Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectar Biosciences could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics of similar companies.Cellectar Biosciences is currently under evaluation in net income category among its peers.
Cellectar Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cellectar Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cellectar Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cellectar Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Cellectar Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cellectar Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cellectar Biosciences' value.| Shares | Advisor Group Holdings, Inc. | 2025-06-30 | 22.0 | Sbi Securities Co Ltd | 2025-06-30 | 11.0 | U.s. Bancorp | 2025-06-30 | 3.0 | Jones Financial Companies Lllp | 2025-06-30 | 3.0 | Bank Of America Corp | 2025-06-30 | 2.0 | Harbour Investments, Inc. | 2025-06-30 | 1.0 | Citigroup Inc | 2025-06-30 | 1.0 | State Street Corp | 2025-06-30 | 0.0 | Bfsg, Llc | 2025-03-31 | 0.0 | Vanguard Group Inc | 2025-06-30 | 56.3 K | Geode Capital Management, Llc | 2025-06-30 | 14.4 K |
Cellectar Fundamentals
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 2.39 M | ||||
| Shares Outstanding | 4.24 M | ||||
| Shares Owned By Insiders | 4.00 % | ||||
| Shares Owned By Institutions | 7.69 % | ||||
| Number Of Shares Shorted | 193.02 K | ||||
| Price To Earning | (1.35) X | ||||
| Price To Book | 1.87 X | ||||
| EBITDA | (51.49 M) | ||||
| Net Income | (44.58 M) | ||||
| Cash And Equivalents | 24.81 M | ||||
| Cash Per Share | 4.06 X | ||||
| Total Debt | 494 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.51 X | ||||
| Book Value Per Share | 2.34 X | ||||
| Cash Flow From Operations | (47.58 M) | ||||
| Short Ratio | 1.39 X | ||||
| Earnings Per Share | (8.07) X | ||||
| Target Price | 47.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 13.74 M | ||||
| Total Asset | 25.47 M | ||||
| Retained Earnings | (247.34 M) | ||||
| Working Capital | 14.86 M | ||||
| Current Asset | 8.14 M | ||||
| Current Liabilities | 1.39 M | ||||
| Net Asset | 25.47 M |
About Cellectar Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectar Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectar Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectar Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. Projected growth potential of Cellectar fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cellectar Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Cellectar Biosciences requires distinguishing between market price and book value, where the latter reflects Cellectar's accounting equity. The concept of intrinsic value—what Cellectar Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cellectar Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Cellectar Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cellectar Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cellectar Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.